Hjem › Ikke-småcellet lungekreft › Illinois › Joliet
Kliniske studier for Ikke-småcellet lungekreft i Joliet, IL
12 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Joliet (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi unna
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi unna
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi unna
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi unna
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekruttererFase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi unna
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RekruttererFase 2
- Hope and Healing Clinical Research, New Lenox · 6 mi unna
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- University of Chicago, New Lenox · 6 mi unna
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekruttererFase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi unna
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox · 6 mi unna
- The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park · 14 mi unna
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi unna
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi unna
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi unna
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi unna
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Joliet
- Lungekreft12 studier
- Blærekreft7 studier
- Metastatisk kreft7 studier
- Plateepitelcancer i hode og hals6 studier
- Prostatakreft5 studier
- Akut myelogen leukemi5 studier
- Hypofarynxcancer5 studier
- Larynxcancer5 studier
- Munnhulekreft5 studier
- Brystkreft4 studier
- Eggstokkreft4 studier
- Tykktarmskreft4 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.